Acute coronary syndrome in patients with carbohydrate metabolic disturbances (A REVIEW)


Cite item

Full Text

Abstract

The review gives the results of large clinical studies of the prognostic value of hyperglycemia in patients with acute coronary syndrome and discusses the basic mechanisms determining the increased cardiovascular risk. The advantages of invasive treatment policy are also described in diabetic patients with an exacerbation of coronary heart disease.

References

  1. Juutilainen A. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabet. Care 2004; 27: 2898-2904.
  2. Marso S. P., Lincoff M., Ellis S. G. et al. Optimizing the percutaneous outcome for patients with diabetes mellitus. Results of the EPISCENT Diabetic Substudy. Circulation 1999; 100: 2477-2484.
  3. Marks J. B., Raskin P. Cardiovascular risk in diabetes. J. Diabet. Complicat. 2000; 14: 108-115.
  4. Дедов И. И., Шестакова М. В., Максимова М. А. Федеральная целевая программа "Сахарный диабет". М.; 2002.
  5. Амосова Е. Н. Особенности инфаркта миокарда у больных сахарным диабетом. В кн.: Материалы Научно-практической конференции "Актуальные вопросы клинической кардиологии". Харьков: 2004.
  6. Angular D., Solomon S., Kober L. et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction, the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Circulation 2004; 21: 1572- 1578.
  7. Goyal A., Mahaffey K., Gard J. et al. Prognostic significance of the change in glucose level in the first 24h after acute myocardial infarction, results from the CARDINAL study. Eur Heart J.2006; 27: 1289-1297.
  8. Kwaan H. C. Abnormalities of hemostasis and fibrinolysis in diabetic patients with empphasis on coronary artery disease. Medicographia 2001; 23: 114-118.
  9. Cosentino F., Eto M., de Paolis P. et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells. Circulation 2003; 107: 1017.
  10. Prasad A., Stone G., Stuckey T. et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 2005; 45: 508-514.
  11. Gowri M. S., Van der Westhuyzen D. R., Bridges S. M. et al. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be to abnormal composition of HDL. Arterioscler. Thromb.Vasc. Biol. 1999; 19: 2226-2233.
  12. Fogelman A. M. From fatty streak to myocardial infarction: an inflammatory response to oxidizes lipids. Circulation 1994; 90: 113.
  13. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91 (11): 2844-2850.
  14. Hackman A., Abe Y., Insal W. et al. Lewels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996; 93: 1334-1338.
  15. Nelken N. A., Goughlin S. R., Gordon D., Wilcox J. N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J. Clin. Invest. 1991; 88: 1121-1127.
  16. Ray K. K., Cannon C. P., Morrow D. A. et al. Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST- elevation acute coronary syndromes: analyses from OPUS TIMI 16 and TACTICS TIMI 18. Eur. Heart J. 2007; 28: 806-813.
  17. Booth G., Stalker Т., Lefer A., Scalia R. Elevated ambient glucose induces acute inflammatory events in the microvasculature, effects of insulin. Am. J. Physiol.. Endocrinol. Metab. 2001; 280: 848-856.
  18. Mehta J. L., Nichols W. W., Mehta P. Neutrophils as potential participants in acute myocardial ischemia. J. Am. Coll. Cardiol. 1988; 11: 1309-1316.
  19. Kersten J., Schmeling Т., Orth K. et al. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am. J. Physiol. Heart Circ. Physiol. 1998; 275: 721-725.
  20. Kersten J., Toller W., Tessmer J. et al. Hyperglycemia reduces coronary collateral blood flow through a nitric oxide -mediated mechanism. Am. J. Physiol. Heart Circ. Physiol. 2001; 281: 2097-2104.
  21. Fox K. F., Cowil M. R., Wood D. A. et al. New perspectives on heart failure due to myocardial ischaemia. Eur. Heart J. 1999; 20: 256-262.
  22. Дедов И. И., Александров А. А. Диабетическое сердце: Causa Magna. Сердце 2004; 3 (1): 5-8.
  23. Bartnik M., Ryden L., Ferrari R. et al. Euro Heart Survei Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur. Heart J. 2004; 25: 1880-1890.
  24. Norhammar A., Tenerz A., Nilsson G. et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-2144.
  25. Бабаева Л. А., Толкачева В. В., Тигай Ж. Г. Нарушения углеводного обмена у пациентов с острым инфарктом миокарда без анамнеза сахарного диабета. Клин. фармакол. и тер. 2005; 14 (5): 84-87.
  26. Malmberg К., Norhammar A., Wedel H., Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999; 99: 2626-2632.
  27. McGuire D. K., Emanuelsson H., Granger C. B. et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO-IIb Investigators. Eur. Heart J. 2000; 21: 1750-1758.
  28. Bhadriraju S., Cannon C. P., DeFranco A. C. et al. Association between blood glucose and long term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 Trial. Circulation 2003; 108: 1475.
  29. Franklin K., Goldberg R. J., Spenser F. et al. The GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch. Intern. Med. 2004; 164: 1457-1463.
  30. Malmberg К., Ryden L., Wedel H. et al. Waldenstrom for the DIGAMI 2 Investigator Intence metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on and morbidity. Eur. Heart J. 2005; 26: 650-651.
  31. Pinto D. S., Skolnick A. H., Kirtane A. J. et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 2005; 46: 178-180.
  32. Cannon C. P., Weintraub W. S., Demopoulos L. A. et al. Treat angina with aggrastat and determine cost of therapy with invasive or conservative strategy - thrombolysis in myocardial infarction 18. N. Eng. J. Med. 2001; 344: 1879-1887.
  33. Stone P., Muller J., Hartwell T. et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J. Am. Coll. Cardiol. 1989; 14: 49-57.
  34. Jacoby R., Nesto R. Acute myocardial infarction in the diabetic patients: pathophysiology, clinical course, and prognosis. J. Am. Coll. Cardiol. 1992; 20: 736-744.
  35. Granger C. B., Callif R. M., Young S. et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J. Am. Coll. Cardiol 1993; 21 (4): 920-925.
  36. Bartnik M., Mamberg K., Norhmmar A. et al. Newly detected abnormal glucose tolerance: a important predictor of long- term outcome after myocardial infarction. Eur. Heart J. 2004; 25: 1990-1997.
  37. Bolk J., van der Ploeg Т., Cornel J. et al. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int. J. Cardiol. 2001; 79: 207-214.
  38. Foo K., Cooper J., Deaner A. et al. A single serum glucose measurement predicts adverse outcome across the whole range of acute coronary syndromes. Heart 2003; 89: 512-516.
  39. Suleiman M., Hammerman H., Boulos M. et al. Fasting glucose is the important risk factor for 30-day mortality in patients with acute myocardial infarction. A prospective study. Circulation 2005; 111: 754-760.
  40. The DECODE study group. Glucose tolerance and mortality, comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999; 354: 617-621.
  41. Guidelines on diabetes, pre-diabetes, and cardiovascular disease. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2007; 9 (suppl. C): 1-74.
  42. Lagerqvist В., Husted S., Kontny F. et al. The FRISC-II Investigators. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease. J. Am. Coll. Cardiol 2002; 40: 1902-1914.
  43. Silva J. A., Ramee S. R., White C. J. et al. Primary stenting in acute infarct myocarde: Influence of diabetes mellitus in angiographic results and clinical outcome. Am. Heart J. 1999; 138: 446-455.
  44. Stenestrand U., Wallentin L. Early revascularization and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study. Lancet 2002; 359: 1805-1811.
  45. Kastrati A., Schomig A., Elezi S. et al. Predictive factors of restenosis after coronary steut placement. J. Am. Coll. Cardiol. 1997; 30: 1428-1436.
  46. Iakovou L., Schmidt Т., Bonizzomi E. et al. Incidence, predictors, and outcome of thrombosis after succeful implantation of drug-eluting stents. J. A. M. A. 2005; 293: 2126-2130.
  47. Marso S. P., Lincoff A. M., Ellis S. G. et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 1999; 100: 2477-2484.
  48. Elezi S., Kastrati A., Pache J. et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J. Am. Coll. Cardiol. 1998; 32: 1866-1873.
  49. Moses J. W., Leon M. B., Popma J. J. et al. SIRIUS Investigators. Sirolimus eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 2003; 349: 1315-1323.
  50. Stone G. W., Ellis S. G., Cox D. A. et al. TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 2004; 350: 221-231.
  51. Mehta S. R., Yusuf S., Peters R. J. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
  52. Steinhubl S. R., Berger P. B., Mann J. T. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J. Am. Med. As. 2002; 288: 2411-2420.
  53. Sabatine M. S., Cannon C. P., Gibson C. M. et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARiTY study. J. Am. Med. A. 2005; 294: 1224-1232.
  54. COMMIT Trial Collaborative Group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-1621.
  55. Angiolillo D. J., Fernandez-Ortiz A., Bernardo E. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J. Am. Coll. Cardiol. 2007; 49: 1505-1516.
  56. Angiolillo D. J., Capranzano P., Goto S. et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J. 2008; 29: 2202-2211.
  57. Lee S. W., Park S. W., Kim Y. H. et al. DECLARE-Long Study Investigators. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am. J. Cardiol. 2007; 100: 1103-1108.
  58. Biondi-Zoccai G. G. L., Lotrionte M. L., Anselmino M. et al. Systematic review and meta - analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am. Heart J. 2008; 155: 1081-1089.
  59. Lee S. W., Park S. W., Kim Y. H. et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drag -Eluting Stent Implantation in Diabetic Patients). J. Am. Coll. Cardiol. 2008; 51: 1181-1187.
  60. Dudek D., Dziewierz A., Chyrchel B. et al. Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients (ISAR-REACT 2 insight). Eur. Heart J. 2007; 9 (suppl. A): 2531.
  61. Detre K. M., Lombardero M. S., Brooks M. M. et al. The effect of previous coronary artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. N. Engl. Med. 2000; 342: 989-997.
  62. Abizaid A., Costa M. A., Cantemero M. et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) Trial. Circulation 2001; 104: 533-538.
  63. Gundersen Т., Syekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabet. Care 1983; 6: 285- 290.
  64. Malmberg K., Herlitz J., Hjalmarson A., Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur. Heart J. 1989; 10: 423-428.
  65. Lowel H., Koenig W., Engel S. et al. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population - based myocardial infarction register follow-up study. Diabetologia 2000; 43 (2): 218-226.
  66. Moye L. A., Pfeffer M. A., Wun C. C. et al. Uniformitig of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur. Heart J. 1994; 15: 2-8.
  67. Gustafsson I., Torp-Pedersen C., Kober L. et al. Effect of the angiotensin -converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trane Study Group. J. Am. Coll. Cardiol.1999; 34: 83-89.
  68. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Six- month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI -3 trial. J. Am. Coll. Cardiol.1996; 27: 337-344.
  69. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваск. тер. и профилакт. 2008; 6 (прил. 4): 1-40.
  70. American Diabetes Association: Position statement: Management of dyslipidemia in adults with diabetes. Diabet. Care 2003; 26 (suppl. 1): 83-86.
  71. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol-lowering in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361: 2005-2016.
  72. Cannon C. P., Braunwald E., McCabe C. H. et al. for the Pravastatin or Atorvastatin. Evaluation and infection tfherapy - thrombolysis in myocardial tnfarction 22 investigators. Intensive versus moderate lipid - lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350: 1495-1504.
  73. Raz I., Wilson P. W. F., Strojek К. et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial. Diabet. Care 2009; 32 (3): 381-386.
  74. ADVANCE Collaborative Group et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008; 358: 2560-2572.
  75. Dluhy R. G., McMahon G. T. Intensive glycemic control in the ACCORD and ADVANCE trials. N. Eng. J. Med. 2009; 358 (2): 2630-2633.
  76. Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Eng. J. Med. 2009; 360: 129-139.
  77. Skyler J. S., Bergenstal R., Bonow R. O. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE and VA Diabetes Trials. J. Am. Coll. Cardiol. 2009; 53 (3): 298-304.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies